arginase/neoplasms

The sequence listing that is contained in the file named "GGEOP0002USC2_ST25.txt", which was created on Nov. 17, 2014, is filed herewith by electronic submission and is incorporated by reference herein. BACKGROUND OF THE INVENTION 1. Field of the Invention The invention generally relates to

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention generally relates to compositions and methods for the treatment of cancer with enzymes that deplete L-Arginine in serum. In some embodiments, the cancer is one that does not express, or is otherwise deficient in, argininosuccinate

FIELD OF THE INVENTION The present invention relates to the modification of an arginase for the purpose of increasing the enzyme's serum or circulating half-life and improving its pharmacokinetic properties, in vivo biological activity, stability, and reducing the immune reaction (immunogenicity) to

FIELD OF THE INVENTION The present invention relates to the modification of an arginase for the purpose of increasing the enzyme's serum or circulating half-life and improving its pharmacokinetic properties, in vivo biological activity, stability, and reducing the immune reaction (immunogenicity) to

BACKGROUND Cancer is characterized by the uncontrolled growth of cells in the body, leading to the invasion of essential organs and often death. Initially, the pharmacological treatment of cancer utilized non-specific cytotoxic agents that targeted all rapidly dividing cells, including normal cells.

BACKGROUND Cancer is characterized by the uncontrolled growth of cells in the body, leading to the invasion of essential organs and often death. Initially, the pharmacological treatment of cancer utilized non-specific cytotoxic agents that targeted all rapidly dividing cells, including normal cells.

BACKGROUND Cancer is characterized by the uncontrolled growth of cells in the body, leading to the invasion of essential organs and often death. Initially, the pharmacological treatment of cancer utilized non-specific cytotoxic agents that targeted all rapidly dividing cells, including normal cells.

BACKGROUND Antigens expressed by tumor cells are an increasingly popular target for the development of immunotherapeutics in the treatment of cancer. Vaccines against such antigens have been developed in hopes of directing an immune response against tumors causing attenuation and regression of tumor

BACKGROUND Antigens expressed by tumor cells are an increasingly popular target for the development of immunotherapeutics in the treatment of cancer. Vaccines against such antigens have been developed in hopes of directing an immune response against tumors causing attenuation and regression of tumor

BACKGROUND Antigens expressed by tumor cells are an increasingly popular target for the development of immunotherapeutics in the treatment of cancer. Vaccines against such antigens have been developed in hopes of directing an immune response against tumors causing attenuation and regression of tumor

BACKGROUND The present invention refers to a method for inducing tumor apoptosis by influencing the ROS (reactive oxygen species) signaling pathway in tumor cells. Increasing the level of ROS leads to the selective inactivation of a tumor cell catalase and subsequently to an apoptosis of these

This application corresponds to the national phase of International Application No. PCT/E07/006964, filed Aug. 7, 2007, which, in turn, claims priority to European Patent Application No. 06.18120.3, filed Aug. 30, 2006, the contents of both of which are incorporated by reference herein in their

BACKGROUND Cancer is characterized by the uncontrolled growth of cells in the body, leading to the invasion of essential organs and often death. Initially, the pharmacological treatment of cancer utilized non-specific cytotoxic agents that targeted all rapidly dividing cells, including normal cells.

BACKGROUND Cancer is characterized by the uncontrolled growth of cells in the body, leading to the invasion of essential organs and often death. Initially, the pharmacological treatment of cancer utilized non-specific cytotoxic agents that targeted all rapidly dividing cells, including normal cells.

CROSS-REFERENCE TO RELATED APPLICATION This application is a U.S. national entry application under 37 C.F.R. .sctn. 371(b) of International Application Serial No. PCT/GB2016/050408 filed Feb. 18, 2016, which claims the right of priority and benefit under 35 U.S.C. .sctn..sctn. 119 & 365 of GB